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ABSTRACT
Objective An epidemic of acute hepatitis C virus (HCV)
infection in HIV-positive men-who-have-sex-with-men
(MSM) is emerging in Europe, Australia and the USA.
The aim of this study was to characterise the natural
history of primary HCV in this setting and to assess host
and viral factors which predict spontaneous clearance.
Methods This prospective longitudinal cohort study was
carried out in 112 HIV-positive patients who were
followed in a single centre (the St Mary’s Acute HCV
Cohort). Plasma and peripheral blood mononuclear cells
(PBMCs) were obtained at monthly intervals for
3 months and at 3-monthly intervals thereafter for
a median of 45 months (IQR¼29e69 months). The
primary end point was spontaneous clearance of HCV.
Cox regression was used to assess the impact of clinical
and virological variables on outcome, including liver
function, CD4 count, rate of HCV RNA decline, T cell
response and clonal sequence evolution within the HCV
E2 envelope gene.
Results 15% of patients cleared HCV spontaneously,
while 85% progressed towards chronicity. The latter
group included a significant proportion of ‘fluctuating’
progressors (37.5%), in whom a fall followed by a rise
(>1 log10) in viraemia was observed. This was
associated with superinfection with new HCV strains and
partially effective T cell responses. Spontaneous
clearance was strongly associated with a 2.2 log10 viral
load drop within 100 days of infection (HR¼1.78;
p<0.0001), elevated bilirubin ($40 mmol/l; HR¼5.04;
p¼0.006), elevated alanine aminotransferase (ALT;
$1000 IU/ml; HR¼2.62; p¼0.048) and baseline CD4
count $6503106/l (HR¼2.66; p¼0.045), and only
occurred in patients with genotype 1 infection. Evolution
to spontaneous clearance occurred in patients with low
viral diversity in the presence of an early multispecific
T cell response.
Conclusions Spontaneous clearance of acute HCV in
HIV-positive men can be predicted by a rapid decline in
viral load, high CD4 count, elevated bilirubin and ALT, and
is associated with low viral diversity and strong T cell
responses.
Twenty-one years after the discovery of the hepa-
titis C virus (HCV) genome,1 the asymptomatic
nature of early infection has meant that its natural
history has only been partially described. Exposure
to the virus is usually unnoticed by patients until
they develop cirrhosis of the liver or hepatocellular
carcinoma following many years of silent infection.
Thus, while large cohorts of patients with chronic
infection have been extensively described, insights
into early hostevirus dynamics have been less well
characterised. Follow-upof point-sourceoutbreaksd
for example, nosocomial infection in hospitals and
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Significance of this study
What is already known about this subject?
< Acute HCV is an emerging epidemic in HIV-
positive MSM in Europe, Australia and the USA.
< Clinical measures such as elevated bilirubin and
symptomatic disease have been associated with
spontaneous clearance (SC) in small cohorts of
patients.
< Small studies in HIV-negative individuals indi-
cate that SC may be predicted by viral
diversification and host T cell function.
What are the new findings?
< Three patterns of infection occur in HIV-infected
patients with acute HCV infection: SC, fluctu-
ating viraemia (FV) and plateau viraemia (PV).
< SC may be predicted by a 2.2 log10 viral load
(VL) drop within 100 days of infection. FV
patients have a slower rate of VL decline than
SC patients, even if a negative VL is achieved.
< A low rate of viral diversification associated
with an early multispecific T cell response is
predictive of SC in HIV-positive MSM.
< HCV superinfection (resulting in multiple HCV
strain infections) is common in HIV-positiveMSM.
How might it impact on clinical practice in the
foreseeable future?
< Currently available treatment for HCV (pegylated
interferon a and ribavirin) is toxic and expensive.
< Early identification of individuals likely to
progress to chronic infection using sequential
viral load measurements is useful in decisions
regarding the necessity and timing of treatment.
< Measures of viral diversity and T cell function
are also predictive of outcome and may be
useful in the future for identifying patients at
high risk of progressing to chronicity.
< Once infected with HCV, HIV-positive MSM are
at risk of superinfection with new HCV strains.
Patients should be encouraged to use condoms
with sexual partners (even if already HIV and
HCV infected) and to use clean needles and
injection equipment if they use intravenous or
intramuscular drugs.
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rhesus-negative women who received contaminated immuno-
globulin during pregnancydhave provided valuable insights
into transmission risks and the likelihood of spontaneous
clearance.2 3 One large multicentre community-based study of
patients mainly infected by iatrogenic exposure or intravenous
drug use revealed that viral clearance usually occurs within
3 months.4 This was recently observed in another longitudinal
study of intravenous drug users in whom female sex was also
associated with spontaneous clearance.5
Very little is known about early HCV in HIV-infected indi-
viduals, in whom HCV is emerging as a major concern, with
liver disease now a major cause of mortality in patients with
access to highly active antiretroviral therapy.6 Globally, 4e5
million people are infected with both viruses, due to shared
routes of transmission.7 An emerging epidemic of acute HCV
infection in HIV-positive men in urban centres in Europe,8 9
Australia10 and the USA11 has provided a rare opportunity to
study the progression of early disease prospectively in a large
number of individuals. Patients are identiﬁed early in infection,
despite lack of symptoms, due to the detection of abnormal liver
function tests at routine clinic follow-up.
The majority of patients infected acutely with HCV progress
to chronic infection (55e90%). A number of mechanisms may
be responsible for the persistence of virus in these individuals.
The virus has an extremely rapid generation timedproducing
on average, a trillion viral particles every day. Furthermore, the
viral genome is copied imperfectly due to the lack of proof-
reading function of the viral RNA polymerase.12 The result is
the production of a swarm of related, but genetically different
viral sequences that circulate at any given time; the quasispecies.
The ability of the host immune system to recognise and
eliminate each variant strain is highly likely to inﬂuence the
ﬁnal outcome. In a small, well-characterised cohort (n¼12) of
HIV-negative individuals, it has been shown that those who
progress to chronicity have higher viral diversity than those
who clear the virus spontaneously.13 Evolution of the hyper-
variable region-1 (HVR-1) of the viral envelope-2 (E2) protein,
which contains both B and T cell epitopes, is associated with
progressive disease, while a narrowed quasispecies repertoire
occurs in patients who subsequently spontaneously clear infec-
tion. Spontaneous clearance (SC) of virus in HIV-negative indi-
viduals is accompanied by the emergence of strong multispeciﬁc
CD8+ and CD4+ cell responses targeting a broad range of
viral epitopes.14e17 Less is known about the natural history of
early HCV infection in HIV-positive individuals despite the fact
that dual infection is commonplace due to shared routes of
transmission.
In this study, a cohort of 112 prospectively followed
HIV-positive patients infected with acute HCV was used to
characterise clinical patterns of infection and identify parame-
ters predictive of SC, based on host factors such as CD4
count, liver function and sequential viral load (VL) sampling.
Longitudinal genetic sequence analysis and T cell function
determination was carried out in 50 patients (10 clearers and
40 progressors) at multiple time points. We hypothesised that
rapid diversiﬁcation of virus would be expected in patients who
progress to chronicity, while SC of disease would be predicted
by limited quasispecies diversity accompanied by strong T cell
responses.
MATERIALS AND METHODS
Patient cohort
Informed consent in writing was obtained from each patient,
the study protocol conformed to the ethical guidelines of the
1975 Declaration of Helsinki and ethical approval was granted
by the Riverside Research Ethics Committee.
A cohort of 112 patients with HIV and acute HCV (102 with
chronic HIV/acute HCV and 10 with acute HIV/acute HCV
co-infection) were prospectively recruited from 2005 to 2009 in
a single centre (the St Mary’s Acute Hepatitis C Cohort). Plasma
and peripheral blood mononuclear cell (PBMC) samples were
obtained prospectively at monthly intervals for 3 months and at
3-monthly intervals thereafter for a median of 3 years. Stored
frozen samples (HIV VL samples obtained every 3 months
between 1994 and 2009) were also tested retrospectively by
HCV reverse transcriptionePCR (RTePCR) in order to date the
length of HCV infection. The date of infection was calculated as
the midpoint between the last negative PCR or antibody test
and ﬁrst positive HCV PCR.
Patients were offered 48 weeks of treatment with pegylated
interferon a and weight-based ribavirin (800e1200 mg) 12 weeks
following HCV diagnosis unless this was contraindicated or SC
occurred.
Case definition and end points
Acute HCV diagnosis was deﬁned by a positive HCV RNA
RTePCR test within 6 months of a preceding negative RTePCR
or antibody test.
The primary end point of the study was SC of HCV, deﬁned as
two successive negative RTePCR tests (<12 IU/ml) 3 months
apart.
Sustained virological response (SVR) was deﬁned as HCV
RNA negativity (<12 IU/ml) 24 weeks after the end of 48 weeks
of treatment with pegylated interferon a and ribavirin.
VL dynamics, liver function, viral diversity following clonal
analysis and Tcell responses were also assessed at multiple time
points. VL observations were censored at the time of treatment.
Amplification of E2 HVR-1 and NS5B
Viral RNA was extracted using the QIAamp Viral RNA kit
(Qiagen, Crawley, UK). Ampliﬁcation of a 220 bp region
including the E2 HVR-1 and a 376 bp region from NS5B was
carried out by nested RTePCR using a combination of geno-
type-speciﬁc primers18 19 and a One-Step RT-PCR kit (Qiagen).
The HVR-1 is the most heterogeneous section of the HCV
genome and can therefore be used to determine intragenotype
differences in HCV strains.20 Puriﬁed PCR products were cloned
into TOPO-4 vector (Invitrogen, Paisley, UK) and. following
bacterial transformation, 20 colonies per plate were selected and
used for plasmid DNA preparation and sequencing.
Sequence analyses
Sequences were aligned using Clustal W. Phylogenetic trees were
constructed withMEGA 4.0 using the NeighboreJoining method
and Kimura two-parameter distance for all substitutions, and the
inferred phylogenies were tested with 1000 bootstrap replica-
tions. Genetic diversity was calculated using the Hamming
distance, which is deﬁned as the number of amino acid differ-
ences between two sequences using the formula (1s)3100,
where s is the fraction of shared sites in two aligned nucleotide
sequences. Genetic distance was calculated as the mean
percentage difference between all samples at any time point.
Unique strains were deﬁned as those originating from
a distinct branch on the phylogenetic tree with a bootstrap value
of >70 and a >10% genetic distance when compared with other
strains derived from the same patient. Superinfection was
deﬁned as evidence of unique strains not present at baseline
sampling, but evident at a later time point. Mean intrastrain
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corrected genetic distance and Hamming distances were calcu-
lated for all patients.
Non-synonymous substitutions per non-synonymous site
divided by synonymous substitutions per synonymous site
(dN/dS) ratios were calculated using MEGA 4.0. dN/dS values
>1 were considered as evidence of positive selection.
Genetic sequence data
All viral sequences have been submitted to EMBL (accession
numbers: HQ616913-HQ619203).
ELISpot assays
PBMCs were separated from whole blood by density gradient
centrifugation and stored in liquid nitrogen. Thawed PBMCs
were added to 96-well plates coated with mouse antihuman
interferon g (IFNg) antibody. Peptides were added and the cells
were incubated overnight. These were then washed off and
mouse antihuman-IFNg monoclonal antibody and alkaline
phosphatase-conjugated antibiotin monoclonal antibody were
added followed by incubation with 5-bromo-4-chloro-indolyl-
phosphate-nitroblue-tetrazolium. Spot-forming units (SFUs)
were counted on an ELISpot reader. Further details are given in
Appendix 1 available online.
Error rates
In order to exclude contamination error as the mechanism for
superinfection events, multiple time points were assessed and
ampliﬁcation of NS5B was carried out at different time points.
In order to distinguish superinfection from co-infection with
varying dominance of virus, PCR ampliﬁcation was carried out
using strain-speciﬁc primers. Further methodology details,
including measures taken to prevent error, are available in
Appendix 2 online.
Statistical analyses
As appropriate, Cox regression survival analysis, KaplaneMeier
survival plots, ManneWhitney, c2 and Fisher exact tests were
used to analyse the signiﬁcance of observations using the
statistical computer package STATA 10.0. VL observations
were right-censored at the time of treatment or end of follow-
up. HRs were calculated with 95% CIs. p Values of #0.05 were
considered to be statistically signiﬁcant.
RESULTS
Cohort characteristics
A total of 112 patients were recruited to the study and followed-
up for a median of 45 months (IQR¼29e69 months; ﬁgure 1).
Sequential VL measurements revealed three patterns of infection
(ﬁgure 2); progression to chronicity with an initial peak viraemia
and chronic plateau viraemia (PV) phase (47.5%), ﬂuctuating
viraemia (FV) deﬁned as a fall followed by a rise in VL of >1
log10 IU/ml (37.5%); and SC (15%). Demographic and clinical
parameters are shown in table 1.
Sequential bilirubin and alanine aminotransferase (ALT)
measurements and outcome
Early infection in progressors (PV and FV groups) and sponta-
neous clearers (SC) was associated with a rise in ALT and bili-
rubin. The peak SC bilirubin and ALT levels were signiﬁcantly
higher than in the progressor groups (table 1; ﬁgure 2).
Viral dynamics and outcome
SC was associated with an initial increase followed by a rapid
fall in VL (2.2 log10 drop within 100 days and 3.46 log10 drop
within 200 days; table 2) leading to clearance at a median of
108 days (95% CI 38 to 170 days). Thirteen FV patients became
transiently PCR negative, but took on average 154 days to reach
negativity (95% CI¼113, 323 days; p¼0.04). Of the 35 patients
who achieved a 2.2 log10 drop in VL, 17 (49%) spontaneously
cleared infection and 18 (51%) did not. Those who spontane-
ously cleared infection took a median of 45 versus 120 days to
achieve a 2.2 log10 drop in VL (p¼0.01).
Genetic sequence and phylogenetic analyses
Phylogenetic analysis of majority quasispecies compared with
reference sequences revealed several monophyletic clusters of
Figure 1 Patient cohort diagnosis,
treatment and follow-up. A total of 112
HIV-positive patients with acute
hepatitis C virus (HCV) were recruited
to the the St Mary’s Acute HCV Cohort
study of whom 17 spontaneously
cleared HCV. Treatment with pegylated
interferon a (IFNa) and ribavirin was
given for 48 weeks to 62 patients and
withheld or delayed in a further 26. The
sustained virological response rate was
66%. Ab, antibody; LFTs, liver function
tests; RT-PCR, reverse
transcriptionePCR.
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infection within genotype 1a (77%), 4d (15%), 3a (7%) and 1b
(4%), indicating several introductions of the virus into the MSM
population (Appendix 3 online). Six per cent were infected with
two genotypes and 2% had three genotypes (1a, 3a and 4d). SC
occurred only in patients with genotype 1a infection, and this
was signiﬁcantly associated with outcome (p¼0.04).
In order to determine which phylogenetic factors predicted
SC, Hamming distance (diversity), number of quasispecies and
dN/dS ratios were calculated in 50 patients (40 progressors and
10 clearers) at multiple (median¼3) time points (table 3).
Initially, genetic diversity was noted to vary considerably over
time in all groups (Appendix 4 online) but did not correlate with
VL. In order to investigate if this variation was the result of
superinfection events, NeighboreJoining phylogenetic analyses
of all longitudinally acquired E2 HVR-1 sequences (n¼2291) were
next carried out, revealing three groups of patients (ﬁgure 3);
those who spontaneously cleared infection (n¼10; 20%), those
who progressed to chronicity with increasing quasispecies
diversity but no evidence of superinfection (n¼20; 40%); and
those who progressed to chronicity with evidence of superin-
fection events (n¼20; 40%; ﬁgure 5). A number of supplementary
analyses were carried out to conﬁrm these results (Appendix 2
online).
Mean intrastrain calculations of genetic diversity and dN/dS
ratios were used for patients found to have multiple strains of
infection. Following this correction, diversity and dN/dS ratios
increased gradually with time in progressors, but decreased in
clearers (table 3, ﬁgure 4).
T cell responses
IFNg production in response to pooled peptides spanning the
entire viral genome were measured by ELISpot at two time
Figure 2 Clinical measures and
outcome in (A) the whole cohort and
(B) representative individual patients.
Longitudinal hepatitis C virus (HCV)
viral load measurements taken prior to
treatment revealed three patterns of
infection: spontaneous clearance
(SC; 15%, red) and two patterns of
progression (85%); peak and plateau
(PV; 47.5%, black) or fluctuating
viraemia (FV; 37.5%, blue) defined as
a viral load peak followed by a decline
(>1 log10) and subsequent rise in
viraemia (>1 log10). Viral loads (VLs)
obtained from spontaneous clearers
(red), plateau progressors (black) and
fluctuating progressors (blue) groups
were pooled and plotted using a linear fit
model from the time of peak viraemia to
300 days (insert). VL data were
right-censored at the time of treatment
for HCV. Grey shading indicates 95% CIs.
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points in 40 patients with genotype 1a infection. Total responses
at baseline were signiﬁcantly higher in SC versus PV (415 versus
115 SFU/million cells; p¼0.005) and FV (415 versus 50 SFU/
million cells; p¼0.04) patients while responses were not signif-
icantly different by 3e6 months. In FV patients, transient viral
control was associated with strong T cell responses. while viral
relapse was often associated with loss of T cell response
(Appendix 5 online).
SC was associated with signiﬁcantly increased early responses
to NS2/p7, NS3 protease and NS5A when compared with both
PV and FV progressors (ﬁgure 5). SC patients also had signiﬁ-
cantly increased responses to NS3 helicase and NS5B than PV
patients but not FV patients.
Fluctuating viraemia
Patients with a ﬂuctuating VL were more likely to have evidence
of superinfecting strains than those with plateau persistence
(63% vs 29% p¼0.04). However, not all FV patients had evidence
of superinfection. Among those with single strain infection,
persons with recrudescent viraemia had similar dN/dS ratios at
baseline but higher cumulative ratios following a second sample
than plateau progressors (1.78 vs 0.76; p¼0.02). At baseline,
those with single strain recrudescent viraemia had higher viral
diversity (Hamming distance 2.84 vs 0.49; p¼0.04). Peak bili-
rubin, ALT and number of quasispecies did not differ between
Table 1 Clinical measures and outcome (spontaneous clearance vs progression)
Clinical measure
(units, normal range)
Spontaneous clearance
(median, 95% CI)
Progression
Range HR (95% CI) p Valuey
Plateau viraemia
(median, 95% CI)
Fluctuating viraemia
(median, 95% CI)
Number 17 (15%) 53 (47.5%) 42 (37.5%) e e e
Age (years) 37 (32 to 44) 39 (37 to 42) 39 (37 to 40) HR represents change in
hazard per year of age
1.00 (0.94 to 1.06) 1.00
Baseline HCV VL log10 (IU/ml) 6.11 (1.79 to 7.35) 6.25 (5.71 to 6.44) 5.89 (5.06 to 6.13) HR represents change in
hazard per log10 change
in VL
0.75 (0.55 to 1.01) 0.06
Peak HCV VL log10 (IU/ml) 6.11 (1.79 to 7.35) 6.52 (6.36 to 6.88) 6.21 (5.87 to 6.72) 0.61 (0.46 to 0.80) <0.0001**
HIV VL (copies/ml) <50 (<50 to 7044) <50 (<50 to 1185) 87 (<50 to 6847) 1.00 (1.00 to 1.00) 0.40
Elevated bilirubin (0e17 mmol/l) 30 (12 to 60) 16 (14 to 19) 14 (12 to 17) <20 1z
20e40 1.64 (0.48 to 5.6) 0.43
$40 5.04 (1.60 to 15.92) 0.006**
Peak ALT (0e40 IU/l) 347 (128 to 1792) 308 (204 to 420) 500 (316 to 659) <1000 1z
$1000 2.62 (1.01 to 6.80) 0.048*
CD4 count (300e1400 3106/l) 650 (490 to 829) 510 (439 to 640) 520 (453 to 619) <650 1z
$650 2.66 (1.02 to 6.91) 0.045*
Nadir CD4 (300e1400 3106/l) 340 (200 to 519) 310 (280 to 350) 315 (270 to 367) $200 1z
<200 1.51 (0.52 to 4.35) 0.45
Transmission
IDUx 3/13 (23%) 13/44 (30%) 13/36 (36%) All patients were MSM
and had had recent
unprotected sex
1.63 (0.27 to 2.75) 0.36
INDU{ 9/12 (75%) 31/42 (74%) 27/34 (79%) 0.92 (0.25 to 3.46) 0.94
Sexual 14/14 (100%) 46/46 (100%) 39/39 (100%) e e
HAART 11/15 (73%) 31/53 (58%) 23/42 (55%) 1.63 (0.57 to 4.70) 0.36
*Significant p value<0.05, **highly significant p value<0.01.
yp values shown represent all progressors (fluctuating viraemia and plateau viraemia) versus clearer (spontaneous clearance) groups.
zIndicates baseline.
xIntravenous, intramuscular or subcutaneous drug use (crystal methamphetamine, cocaine, anabolic steroids, heroin).
{Intranasal drug use (ketamine, cocaine).
ALT, alanine aminotransferase; HAART, highly active antiretroviral therapy; HCV, hepatitis C virus; MSM, men-who-have-sex-sith-men; VL, viral load.
Table 2 Median viral load (VL) drop in untreated spontaneous clearers and progressors
Spontaneous clearers
(SC) (95% CI)
Progressors
HR* (95% CI) p Value(PV) (95% CI) (FV) (95% CI)
Maximum HCV VL log10 (IU/ml) drop
within 100 days from first positive PCR
2.20 (1.65 to 5.03) 0.03 (e0.33 to 0.23) 0.58 (0.25 to 0.96) 1.78 (1.45 to 2.18) <0.0001y
Maximum HCV VL log10 (IU/ml) drop
within 200 days from first positive PCR
3.46 (1.70 to 7.05) 0.17 (e0.06 to 0.38) 0.85 (0.45 to 1.77) 1.68 (1.40 to 2.02) <0.0001y
*HR represents change in hazard per log10 change in VL.
yHighly significant p value <0.01.
HCV, hepatitis C virus.
Table 3 Viral sequence analyses and predictors of spontaneous
clearance
Clearers
(95% CI)
Progressors
(PV+FV) (95% CI)
p
Value
Number 10 40 e
Baseline quasispecies 3 (2 to 5) 4 (3 to 6) 0.21
Cumulative quasispecies (two
samples taken <150 days apart)
7 (7 to 8) 9 (8 to 12) 0.24
Baseline Hamming distance 0.39 (0.22 to 0.92) 0.64 (0.36 to 2.97) 0.38
Cumulative Hamming distance (two
samples taken <150 days apart)
0.03 (0 to 0.06) 2.045 (0.81 to 10.47) 0.02*
Baseline HVR-1 dN/dS 0 (0 to 0.325) 0.28 (0 to 0.95) 0.18
Cumulative HVR-1 dN/dS (two
samples taken <150 days apart)
0.17 (0 to 0.35) 1.02 (0.71 to 1.84) 0.03*
*Significant p value<0.05.
dN/dS, non-synonymous substitutions per non-synonymous site divided by synonymous
substitutions per synonymous site; FV, fluctuating viraemia; HVR-1, hypervariable region-1;
PV, plateau viraemia.
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these groups. One patient showed evidence of reactivation of
HCV 2 years after successful treatment (ﬁgure 3C).
Response to treatment
Patients who did not achieve spontaneous clearance 12 weeks
following diagnosis were offered treatment with 48 weeks of
IFNa and ribavirin, and 66% achieved an SVR.
DISCUSSION
An emerging epidemic of acute HCV in HIV-positive MSM has
for the ﬁrst time allowed characterisation of the natural history
of early HCV infection in a large number of HIV-positive
patients. Unravelling the determinants of spontaneous clearance
of HCV is crucial in order to increase our understanding of the
biological mechanisms which deﬁne protective immunity and to
improve the management of patients who face a lengthy course
of treatment which is toxic, expensive and not always effective.
HCV infection in HIV-positive individuals is a growing clinical
problem associated with an increased rate of disease progression
and reduced response to treatment.21 In this longitudinal study
of 112 HIV-positive patients with acute HCV, the key predictors
of spontaneous clearance were VL dynamics, liver function, viral
diversity and T cell response.
Three courses of infection were observed, based on VL changes
over time (ﬁgure 2). SC (15%) was associated with a rapid
decrease in VL. Patients who progressed towards chronicity
exhibited two patterns of viraemia; the majority (47.5%) had an
initial rise in VL followed by a PV phase, analogous to that seen
in other chronic viral infections when the rate of viral clearance
Figure 3 Patterns of acute HCV based
on phylogenetic analysis in subjects
1e10. (A) Spontaneous clearance and
plateau progression, (B) fluctuating
viraemia associated with superinfection
and (C) reactivation. A circular
neighbour-joined phylogenetic tree
analysis (Kimura 2-parameter model) of
305 HVR-1 sequences derived from
subjects 1e10 at 2e4 time points is
shown in order to illustrate patterns
observed in different patient groups.
Similar trees were created for 50
patients. Clones derived from each
patient are given a different colour and
those from two representative patients
are shown in further detail (filled circles
represent time point 1, clear circles
time point 2, filled triangles time point 3
and clear triangles time point 4). (A) A
gradual increase in genetic diversity
can be seen in the progressor patient
(black), while clones derived from the
spontaneous clearer (red) reveal
a narrower repertoire. Bootstrap values
greater than 70% are shown. (B) A
patient with evidence of superinfection
is highlighted. Sequences from time
point 4 (clear triangles, red brackets)
consist of a dominant superinfecting
strain (one clone related to the previous
lineage is also present). This patient
had a fluctuating viral load, with
a negative HCV PCR (limit of
detection¼12 IU/ml) between time
points 3 and 4. (C) A case of HCV
reactivation is shown. The patient had
a sustained virological response (PCR
negative 6 months post-treatment)
following 48 weeks of IFNa and
ribavirin. One year later, he developed
a rapid decrease in CD4 count (nadir
106x106/l) and was hospitalised with
Pneumocystis jeroveci pneumonia.
During this time, his ALT became
elevated and HCV RNA was once again
detected in his blood. He denied any
risk factors for reacquisition of HCV.
Branches derived from patient HVR-1
sequences (n¼56) are coloured in filled
green (baseline sample) and open green
(3 years later). These samples derive from the same lineage.
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equilibrates with the rate of viral production. Some patients,
however, developed a pattern of FV (37.5%) characterised by an
initial decline and subsequent rise in VL (>1 log10). This pattern
of viraemia has been observed in HIV-negative individuals and
experimentally infected chimpanzees, but has not previously
been correlated with superinfection and loss of T cell control in
a large longitudinal study.
We aimed to employ the viral kinetics of early HCV infection
to predict subsequent outcome. SC patients had a 2.2 log10 VL
drop versus a 0.03 log10 drop in PV and 0.58 log10 drop in FV
within 100 days of infection (HR¼1.78, p<0.0001; table 2),
increasing to a 3.46 versus 0.17 (PV)/0.85 (FV) log10 drop by
200 days (HR¼1.68; p<0.0001).
Cox regression analysis indicated that the best diagnostic tests
for the prediction of SC were the maximum log10 drop in VL
within 100 days, peak bilirubin ($40 mmol/l), peak ALT
($1000 IU/l) and baseline CD4 count ($6503106/l) (tables 1, 2).
A difﬁculty encountered in predicting the outcome of infec-
tion is in distinguishing between those who will develop a FV
and those who will go on to spontaneously clear infection,
particularly those patients who become transiently RNA nega-
tive. Survival analysis was used to compare the time taken to
a 2.2 log10 drop or a negative VL in FVand SC patients. The time
to a 2.2 log10 drop was signiﬁcantly shorter in SC versus FV
patients (45 vs 120 days; p¼0.01) as was the time to a negative
VL in the 13 FV patients who did not spontaneously clear
infection (108 vs 154 days); thus the rate of decline of viraemia is
key in predicting outcome.
A detailed phylogenetic and genetic sequence analysis of 2291
longitudinally acquired clonal E2 HVR-1 sequences allowed us to
track the impact of superinfection, and to assess whether
measurements of viral diversity and selection had predictive
value. Several monophyletic clusters were present (Appendix 3
online), in keeping with multiple transmission events in the
MSM population, as previously described.22 Within individuals,
the presence of superinfection was suggested by marked
non-linear variation in genetic distance over time (Appendix 3
online). Phylogenetic tree analyses (ﬁgure 3) revealed evidence
of the introduction of new infecting strains in 40%, both of
the same genotype and with new genotypes. This high rate
of superinfection is in keeping with the likely ongoing high
risk behaviour of this group of patients22 and the observation
of reinfection events in other cohorts.23 The majority of
patients with FV had evidence of reinfection with new strains
of HCV (63%). Strain-speciﬁc PCR was carried out to reduce
overestimation of superinfection due the limitations of clonal
analysis.
In order to investigate the inﬂuence of positive selection on
the diversiﬁcation of viral strains, mean intrastrain Hamming
distance and dN/dS ratios were calculated. Both were signiﬁ-
cantly higher in progressors by 150 days of infection, consistent
with similar observations in HIV-negative individuals.13 In the
main, a gradual increase in viral diversity and dN/dS ratio was
observed over time in PV patients as a result of generation of
positively selected variants associated with a signiﬁcantly
weaker Tcell response. In contrast, viral diversity and the dN/dS
ratio decreased gradually in SC patients (table 3, ﬁgure 4) in
association with a strong, multispeciﬁc T cell response.
When patients with superinfection were excluded from the
analysis, genetic diversity at baseline was greater in the FV
group than in the PV group, possibly reﬂecting a more diverse
infecting quasispecies.
FV patients as a group displayed a slow rise in diversity over
time and a rise followed by a fall in the dN/dS ratio. However,
T cell responses, viral diversity and VL were highly variable
in individuals within this group. This variation in FV patients
would be in keeping with a model of partial immune control
and may reﬂect within some individuals a delayed partially
effective immune response and in others the emergence of
escape variants or an unsustained protective immune response
due to B or T cell failure, for example as a consequence of PD-1
receptor upregulation (a marker of T cell exhaustion and disease
progression both in HIV-positive individuals and in acute HCV
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Figure 4 T cell responses and genetic variation within the E2
hypervariable region-1 (HVR-1) over time. Cumulative genetic variation
(corrected Hamming distance and dN/dS ratio (non-synonymous
substitutions per non-synonymous site divided by synonymous
substitutions per synonymous site)) and T cell responses
(interferon g (IFNg) spot-forming units (SFU)/106 cells) were assessed
in each group of patients at two time points (sample 1, range
28e189 days; and sample 2, range 115e246 days from the last
negative PCR test).
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infection24 25). Alternatively, it could represent reinfection with
the same strain of virus, which has been experimentally
demonstrated in the chimpanzee model.26 A third explanation
would be the persistence and re-emergence of virus from sites
outside the bloodstream, for example the liver, PBMCs or the
central nervous system.27 28
Changes observed within the E2 HVR-1 region may reﬂect
direct antibody-driven responses13 29 and indirectly reﬂect T cell
responses to other parts of the genome such as the non-structural
proteins.30 Protective immunity in HIV-negative individuals is
known to be associated with broad and multispeciﬁc CD4 and
CD8 T cell responses.14e17 A higher baseline CD4 count
($6503106/l) was noted in SC patients in this cohort (table 1).
We therefore aimed to ascertain if decreased dN/dS ratios and viral
diversity within E2 in SC and FV patients were related to
a protective T-cell response, by measuring IFNg responses to
overlapping pooled peptides spanning the entire HCV genome.
We found that SC patients exhibited signiﬁcantly stronger
multispeciﬁc IFNg responses within 3 months of infection than
either progressor group (PV, p¼0.006; FV, p¼0.01; ﬁgure 5).
In particular, signiﬁcant differences in response to NS2/p7, NS3
protease and NS5A were detected (SC vs FV and PV groups).
SC patients also had signiﬁcantly increased responses to NS3
helicase and NS5B than PV progressors. Further studies to char-
acterise speciﬁc epitopes within these regions are needed.
One unusual case within the cohort suggested that reac-
tivation of HCV may rarely occur in immunosuppressed indi-
viduals. This patient had evidence of reactivation of HCV
2 years after successful treatment for acute disease (ﬁgure 5C).
This coincided with a period of severe immunosupression (nadir
CD4 count 1063106/l and Pneumocystis jerovecii infection)
requiring hospitalisation and may have been the result of loss of
T cell control of a virus present in the liver but not in the
bloodstream, or extremely low level viraemia below the limit of
detection. Such cases are rare but have been previously reported
in the literature.31
This study is the ﬁrst longitudinal and detailed analysis of
clinical outcome of acute HCV in a large cohort of HIV-positive
patients, incorporating viral dynamics, detailed viral sequence
evolution and T cell responses. It has a number of limitations.
First, it is restricted to an HIV-positive population, although
patterns of evolution during early infection may also apply to
those with HCV monoinfection. Steps were taken to minimise
error rates attributable to PCR contamination and clonal anal-
ysis, as detailed in the Supplementary information online. In
order to overcome the problem of delayed HCV seroconversion
Figure 5 T cell responses across the
hepatitis C virus (HCV) genome at
baseline and 3e6 months. (A) Total T
cell responses and (B) T cell responses
across the HCV genome. T cells
responses to pooled peptides spanning
the entire HCV genome were assessed
by ELISpot in 40 patients with genotype
1a infection at two time points.
Significant results (p<0.05) are
highlighted with asterisks (red indicates
significant difference between SC and
both FV and PV patients; green
indicates significant difference between
SC and PV patients). These responses
were measured in total (A) and to 10
overlapping peptide pools (B) from
across the entire HCV genome.
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in HIV-positive individuals, as previously reported in this
cohort18 (to avoid the inclusion of chronically infected patients),
we used retrospective PCR testing on stored HIV VL samples to
date the time of infection. More work is needed to further deﬁne
speciﬁc Tcell targets and class I/II restriction of these responses,
as well as the impact of viral escape.
Acute HCV infection is an emerging global epidemic in HIV-
infected men and requires new public health planning and
treatment strategies. These data suggest that the outcome of
infection can be predicted by the measurement of VL dynamics
as well as CD4 count and liver function. Lower genetic diversity
and stronger T cell responses are also associated with SC, but
were less useful than clinical measures in predicting outcome.
Targeting of high risk patientsdfor example, with no evidence
of rapid decline in VL within 100 daysdmay increase the efﬁ-
cacy of treatment while those more likely to clear infection
spontaneously could be monitored for a longer period of time,
thus avoiding a rigorous and expensive treatment.
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